Secondary analysis of a trial of 308 patients with early PsA: 25.1% of 235 with oligoarticular disease progressed to polyarticular disease by week 16; apremilast reduced odds of progression v placebo (OR 0.42).
Secondary analysisn = 308
Coates et al. Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: Novel insights from FOREMOST